Skip to main content
Fig. 3 | BMC Neurology

Fig. 3

From: Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Fig. 3

Comparison of SARS-CoV-2 (A) neutralizing Ab, (B) anti-nucleocapsid IgG, and (C) anti-spike IgG levels according to sex, MS phenotype, receiving DMTs, and the specific type of DMTs. Abbreviations: Ab: antibody; DMF: dimethyl fumarate; DMT: disease-modifying therapies; FG: fingolimod; GA: glatiramer acetate; IFN: interferon; MS: multiple sclerosis; ns: nonsignificant; NTM: natalizumab; OCR: ocrelizumab; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; RTX: rituximab; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SPMS: secondary progressive multiple sclerosis; TFM: teriflunomide. Note: The small sample sizes for certain treatments (e.g., natalizumab and teriflunomide) may limit the robustness of comparison of their immunogenicity. *P value < 0.05. **P value < 0.01. ***P value < 0.001. ****P value < 0.0001

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us